EBIT: Income before interest and taxes.
Lyell Immunopharma, Inc. (LYEL) had EBIT of $-127.64M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$0.01M |
|
$-140.72M |
|
-- |
|
$0.01M |
|
$127.65M |
|
$-127.64M |
|
$-13.08M |
|
$-140.72M |
|
$-140.72M |
|
$-140.72M |
|
$-140.72M |
|
$-140.72M |
|
$-140.72M |
|
|
EBIT |
$-127.64M |
$-126.31M |
|
17.09M |
|
17.09M |
|
$-7.44 |
|
$-7.44 |
|
| Balance Sheet Financials | |
$260.94M |
|
$34.77M |
|
$79.11M |
|
$340.05M |
|
$49.41M |
|
-- |
|
$42.44M |
|
$91.85M |
|
$248.20M |
|
$248.20M |
|
$248.20M |
|
21.25M |
|
| Cash Flow Statement Financials | |
$-150.02M |
|
$54.10M |
|
$50.41M |
|
$107.29M |
|
$61.77M |
|
$-45.52M |
|
$41.83M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.28 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-2127401.00% |
|
-2127401.00% |
|
-- |
|
-2345385.00% |
|
-2345384.00% |
|
$-191.71M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-56.70% |
|
-56.70% |
|
-41.38% |
|
-56.70% |
|
$11.68 |
|
$-11.22 |
|
$-8.78 |
|